A phase II study of Velcade (bortezomib, PS-341) and rituximab in relapsed/refractory mantle cell and follicular non-Hodgkin's Lymphoma.

Trial Profile

A phase II study of Velcade (bortezomib, PS-341) and rituximab in relapsed/refractory mantle cell and follicular non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2012

At a glance

  • Drugs Bortezomib (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 11 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top